查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
深奧測試市場規模、佔有率、趨勢：按技術、類型、檢體、最終用戶、地區分類 - 到 2029 年的預測
市場調查報告書
商品編碼
1491986

深奧測試市場規模、佔有率、趨勢：按技術、類型、檢體、最終用戶、地區分類 - 到 2029 年的預測

Esoteric Testing Market Size, Share & Trends by Type, Technology, Specimen - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 295 Pages | 訂單完成後即時交付

價格
簡介目錄

預計 2024 年全球深奧測試市場規模將達到 322 億美元，預計複合年成長率為 8.5%，到 2029 年將達到 483 億美元。

深奧測試市場的成長主要是由慢性病和感染疾病的盛行率不斷增加、個人化醫學深奧測試的進步以及精準醫學研究經費的增加所推動的。

調查範圍
調查年份 2022-2029
基準年 2023年
預測期 2024-2029
考慮單位 金額（十億美元）
部分 按技術、類型、檢體、最終用戶、地區
目標區域 北美、歐洲、亞太地區、中東/非洲、拉丁美洲、海灣合作理事會國家

按類型分類，深奧測試市場分為傳染病檢查、自體免疫疾病測試、內分泌測試、腫瘤學測試、基因測試、毒理學/藥物監測測試、神經系統測試和其他測試。腫瘤學測試用於確定癌症的遺傳風險，對於診斷、預後和治療決策至關重要。癌症盛行率的上升和各種深奧測試的採用增加推動了腫瘤學測試領域的成長。

深奧的檢測市場依技術分為化學冷光免疫檢測（CLIA）、酵素結合免疫吸附檢測法（ELISA）、即時PCR、層析法和質譜、流式細胞技術、DNA定序和次世代定序等技術。越來越多的配備先進 CLIA 技術的專業診斷實驗室以及早期診斷的需求使得在全球範圍內使用 CLIA 測試成為必要。該公司積極的研發支出以及化學冷光生物晶片、多重檢測和可攜式免疫測量等創新技術的開發也預計將在未來幾年支持 CLIAs 市場的成長。

依檢體，深奧檢測市場分為血液、血清、血漿、尿液和其他檢體。該細分市場所佔的很大佔有率是由於全球捐血數量的增加以及全球慢性和感染疾病率的增加。在深奧檢測中使用血液作為檢體是由於其微創性、綜合生物標記潛力和技術進步。這些因素，加上對個人化醫療、監管支援和高效傳染病檢查日益成長的需求，正在推動基於血液的深奧檢測的成長。

依最終用戶分類，深奧的測試市場分為獨立參考實驗室和醫院實驗室。對個人化醫療的需求、慢性病和遺傳疾病的日益流行以及對具有成本效益和高效的診斷解決方案的需求將推動參考實驗室在未來幾年在深奧的測試市場中營運，這是增加重要性的主要成長要素。

該報告研究了全球深奧測試市場，包括按技術、類型、檢體、最終用戶、地區和進入市場的公司概況分類的趨勢。

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第 4 章重要考察

第5章市場概況

  • 介紹
  • 市場動態
  • 價格分析
  • 價值鏈分析
  • 供應鏈分析
  • 深奧的測試市場生態系統分析
  • 監理概覽
  • 技術分析
  • 專利分析
  • 2024-2025年重大會議和活動
  • 波特五力分析
  • 主要相關人員和採購標準
  • 影響客戶業務的趨勢/干擾
  • 投資金籌措場景

第6章 深奧的測試市場，依技術分類

  • 介紹
  • 化學冷光免疫檢測
  • 酵素免疫分析法
  • 即時PCR
  • DNA定序與次世代定序
  • 流式細胞技術
  • 層析法和質譜分析
  • 其他

第 7 章 深奧測驗市場（按類型）

  • 介紹
  • 腫瘤檢查
  • 自體免疫疾病檢測
  • 傳染病檢查
  • 內分泌檢查
  • 基因檢測
  • 神經學檢查
  • 毒理學和藥物監測測試
  • 其他

第 8 章 深奧的測驗市場，依檢體

  • 介紹
  • 血液、血清、血漿
  • 尿
  • 其他

第 9 章 最終用戶深奧的測試市場

  • 介紹
  • 獨立/參考實驗室
  • 醫院實驗室

第10章 深奧的測試市場，按地區

  • 介紹
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲
  • 海灣合作理事會國家

第11章競爭格局

  • 概述
  • 主要參與企業的策略/秘密
  • 收益佔有率分析
  • 市場佔有率分析
  • 企業評估矩陣：主要參與企業，2023
  • 企業評估矩陣：Start-Ups/小型企業，2023 年
  • 競爭場景
  • 深奧的測試供應商評級和財務指標

第12章 公司簡介

  • 主要參與企業
    • LABCORP
    • QUEST DIAGNOSTICS
    • OPKO HEALTH, INC.
    • HU GROUP HOLDINGS, INC.
    • SONIC HEALTHCARE LIMITED
    • MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH（MFMER）
    • EUROFINS SCIENTIFIC
    • STANFORD HEALTH CARE
    • FOUNDATION MEDICINE, INC.
    • KINDSTAR GLOBALGENE TECHNOLOGY, INC.
    • GEORGIA ESOTERIC & MOLECULAR LABORATORY, LLC
    • THYROCARE TECHNOLOGIES LIMITED
    • ACM GLOBAL LABORATORIES
  • 其他公司
    • NMS LABS
    • HEALTHQUEST ESOTERICS
    • CERBA XPERT
    • LEOLABS, INC.
    • FLOW HEALTH
    • INVITAE CORPORATION
    • MYRIAD GENETICS, INC.
    • ARUP LABORATORIES
    • FULGENT GENETICS
    • BIOMONTR LABS
    • LABGENOMICS

第13章附錄

簡介目錄
Product Code: MD 5930

The global esoteric testing market is valued at an estimated USD 32.2 billion in 2024 and is projected to reach USD 48.3 billion by 2029, at a CAGR of 8.5% during the forecast period. Growth in the esoteric testing market is primarily driven by the increasing prevalence of chronic and infectious diseases, advancements in esoteric tests for personalized medicine, and increasing research funding for precision medicine.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD) Billion
SegmentsType, Technology, Specimen, End User, and region
Regions coveredNorth America, Europe, Asia Pacific, Middle East & Africa, Latin America, and the GCC Countries

"The Oncology testing segment accounted for the highest CAGR of the esoteric testing market in 2023, by type"

Based on type, the esoteric testing market is segmented into infectious disease testing, autoimmune disease testing, endocrinology testing, oncology testing, genetic testing, toxicology and drug monitoring testing, neurology testing, and other types of testing. Esoteric oncology tests are used to determine the hereditary risk of cancer and are essential in diagnosis, prognosis, and treatment decisions. The growth of the oncology testing segment is driven by the rising prevalence of cancer and the increased adoption of various esoteric tests.

"The chemiluminescence immunoassay (CLIA) segment is projected to witness highest growth rate in the esoteric testing market, by technology, during the forecast period."

The esoteric testing market is segmented into chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), real-time PCR, chromatography and mass spectrometry, flow cytometry, DNA sequencing and next-generation sequencing, and other technologies, based on technology . Growth in the number of specialized diagnostic laboratories equipped with advanced CLIA technology and the need for early diagnosis have necessitated the use of CLIA tests across the globe. Aggressive R&D expenditures by players and the development of innovative technologies such as chemiluminescent biochips, multiplexed assays, and portable immunoassays are also expected to support the growth of the CLIAs market in the coming years.

"The blood, serum, and plasma segment accounted for the largest market share of esoteric testing market, in 2023, by specimen"

Based on specimens, the esoteric testing market is segmented into blood, serum, and plasma, urine, and other specimens. The large share of this segment is attributed to the growing number of blood donations globally and the increasing incidence of chronic & infectious diseases worldwide.The use of blood as a specimen in esoteric testing is driven by its minimally invasive nature, comprehensive biomarker potential, and technological advancements. These factors, coupled with the growing emphasis on personalized medicine, regulatory support, and the need for efficient infectious disease testing, are propelling the growth of blood-based esoteric tests.

"The independent & reference laboratories segment accounted for the largest share of the esoteric testing market in 2023, by end user".

Based on end users, the esoteric testing market is segmented into independent & reference laboratories and hospital-based laboratories. The demand for personalized medicine, the increasing prevalence of chronic and genetic diseases, and the need for cost-effective and efficient diagnostic solutions are key growth factors driving the importance of reference laboratories operating in the esoteric testing market in the coming years.

"The Asia Pacific region is projected to witness highest growth rate in the esoteric testing market during the forecast period"

The global esoteric testing market is segmented into six regions - North America, Europe, Latin America, Asia Pacific, the Middle East & Africa, and the GCC Countries. The Asia Pacific market, which comprises Japan, Australia, India, China, and the Rest of Asia Pacific, is expected to offer significant growth opportunities to market players and is projected to register the highest CAGR in the esoteric testing market during the forecast period. Government efforts to increase awareness about early disease detection and regular health checkups, rising healthcare expenditure, and the increasing number of hospitals and clinical diagnostic laboratories, and growing awareness regarding the use of esoteric tests among physicians are some of the major factors driving the growth of the esoteric testing market in the Asia Pacific.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 45%, Tier 2 - 38%, and Tier 3 - 17%
  • By Designation: C-level - 24%, D-level - 32%, and Others - 44%
  • By Region: North America - 35%, Europe - 26%, Asia Pacific - 24%, Latin America - 12%, Middle East & Africa - 1%, and the GCC Countries - 2%

Lists of Companies Profiled in the Report:

Quest Diagnostics (US), Labcorp (US), H.U. Group Holdings, Inc. (Japan), Sonic Healthcare (Australia), OPKO Health, Inc. (US), Myriad Genetics, Inc. (US), The Mayo Foundation for Medical Education and Research (MFMER) (US), Eurofins Scientific (Luxembourg), Stanford Health Care (US), Foundation Medicine, Inc. (US), Kindstar Globalgene Technology, Inc. (China), Georgia Esoteric & Molecular Laboratory, LLC (US), Thyrocare Technologies Ltd. (India), ACM Global Laboratories (US), NMS Labs (US), HealthQuest Esoterics (US), Cerba Research (US), LeoLabs (India), Flow Health (US), Invitae Corporation (US), ARUP Laboratories (US), Fulgent Genetics (US), bioMONTR Labs (US), and LabGenomics (South Korea).

Research Coverage:

In this report, the esoteric testing market has been categorized based on technology (enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), real-time PCR, flow cytometry, DNA sequencing and next-generation sequencing, chromatography and mass spectrometry, and other technologies), type (oncology testing, infectious disease testing, autoimmune disease testing, genetic testing, endocrinology testing, toxicology and drug monitoring testing, neurology testing, and other types of testing), specimen (blood, serum, and plasma, urine, and other specimens) end user (independent & reference laboratories and hospital-based laboratories), and region (North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and the GCC Countries).

The report's coverage includes comprehensive details about the key factors impacting the growth of the esoteric testing market, including opportunities, challenges, opportunities, and restraints. To offer insights into their business overview, services offered, significant strategies, acquisitions and partnerships, service launches, and recent developments related to the esoteric testing market, a thorough analysis of the major industry players has been conducted. This study examines the competitive landscape of emerging esoteric testing startups.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall esoteric testing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, challenges, trends, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers: (Advancements in esoteric tests for personalized medicine, increasing research funding for precision medicine, genetic analysis, and personalized medicine, growing number of collaborations), challenges (Dearth of skilled professionals and inaccuracies and misdiagnosis in diagnostic testing), opportunities (Emerging technologies and advanced tests for screening and risk identification in esoteric testing, and advances in understanding heterogeneity of diseases and safety signals), and restraints (Inadequate reimbursement, high capital investments and low-cost-benefit ratio for biomarkers) influencing the growth of the in esoteric testing market.
  • Service Development/Innovation: Detailed insights on research & development activities and new service launches in the esoteric testing market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the esoteric testing market across varied regions.
  • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the esoteric testing market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Quest Diagnostics (US), LabCorp (US), and H.U. Group Holdings, Inc. (Japan), among others, in the esoteric testing market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS OF STUDY
  • 1.3 MARKET SEGMENTATION
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 ESOTERIC TESTING MARKET SEGMENTATION
    • 1.3.2 REGIONS COVERED
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES
    • 1.6.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 ESOTERIC TESTING MARKET: RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Primary sources
      • 2.1.2.2 Key data from primary sources
      • 2.1.2.3 Key industry insights
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
      • 2.2.1.1 Approach 1: Company Revenue Estimation Approach
    • FIGURE 5 COMPANY REVENUE ESTIMATION
    • FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.2.2 TOP-DOWN APPROACH
    • FIGURE 7 ESOTERIC TESTING MARKET: TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 8 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ANALYSIS
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 GROWTH RATE ASSUMPTIONS
  • 2.7 RESEARCH LIMITATIONS
    • 2.7.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.7.2 SCOPE-RELATED LIMITATIONS
  • 2.8 RISK ASSESSMENT
    • TABLE 1 RISK ASSESSMENT
  • 2.9 RECESSION IMPACT ON ESOTERIC TESTING MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 9 ESOTERIC TESTING MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION)
    • FIGURE 10 ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD BILLION)
    • FIGURE 11 ESOTERIC TESTING MARKET, BY SPECIMEN, 2024 VS. 2029 (USD BILLION)
    • FIGURE 12 ESOTERIC TESTING MARKET, BY END USER, 2024 VS. 2029 (USD BILLION)
    • FIGURE 13 GEOGRAPHICAL SNAPSHOT OF ESOTERIC TESTING MARKET

4 PREMIUM INSIGHTS

  • 4.1 ESOTERIC TESTING MARKET OVERVIEW
    • FIGURE 14 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET
  • 4.2 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TECHNOLOGY AND COUNTRY (2023)
    • FIGURE 15 ELISA SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023
  • 4.3 ESOTERIC TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 16 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • 4.4 ESOTERIC TESTING MARKET: REGIONAL MIX (2022-2029)
    • FIGURE 17 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • 4.5 ESOTERIC TESTING MARKET: DEVELOPED VS. DEVELOPING MARKETS
    • FIGURE 18 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 19 ESOTERIC TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing geriatric population and increasing prevalence of chronic and infectious diseases
    • FIGURE 20 INCIDENCE OF CANCER, BY REGION, 2022 VS. 2030 VS. 2040 (MILLION)
    • FIGURE 21 INCIDENCE OF DIABETES, BY REGION, 2021 VS. 2030 VS. 2045 (MILLION)
    • TABLE 2 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
    • FIGURE 22 GERIATRIC POPULATION, BY REGION, 2022 VS. 2050 (%)
    • TABLE 3 ESOTERIC TESTS INDICATED FOR CHRONIC AND INFECTIOUS DISEASES
      • 5.2.1.2 Increasing use of esoteric DNA sequencing technologies in precision medicine and early diagnosis of cancer
      • 5.2.1.3 Advancements in esoteric tests for personalized medicine
      • 5.2.1.4 Increasing research funding for precision medicine, genetic analysis, and personalized medicine
      • 5.2.1.5 Growing number of collaborations
      • 5.2.1.6 Increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Inadequate reimbursement
      • 5.2.2.2 High capital investments and low-cost-benefit ratio for biomarkers
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging technologies and advanced tests for screening and risk identification in esoteric testing
      • 5.2.3.2 Advances in understanding heterogeneity of diseases and safety signals
      • 5.2.3.3 Growth opportunities in emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Dearth of skilled professionals
      • 5.2.4.2 Inaccuracies and misdiagnosis in diagnostic testing
  • 5.3 PRICING ANALYSIS
    • TABLE 4 AVERAGE SELLING PRICE OF ESOTERIC TESTS, BY REGION
  • 5.4 VALUE CHAIN ANALYSIS
    • FIGURE 23 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
  • 5.5 SUPPLY CHAIN ANALYSIS
    • FIGURE 24 ESOTERIC TESTING MARKET: SUPPLY CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS OF ESOTERIC TESTING MARKET
    • FIGURE 25 ESOTERIC TESTING MARKET: ECOSYSTEM ANALYSIS
    • 5.6.1 ROLE IN ECOSYSTEM
    • TABLE 5 ESOTERIC TESTING MARKET: ROLE IN ECOSYSTEM
    • FIGURE 26 KEY PLAYERS IN ESOTERIC TESTING MARKET ECOSYSTEM
  • 5.7 REGULATORY OVERVIEW
    • 5.7.1 NORTH AMERICA
      • 5.7.1.1 US
      • 5.7.1.2 Canada
    • 5.7.2 EUROPE
    • TABLE 6 ACCREDITATION BODIES IN EUROPE
    • 5.7.3 ASIA PACIFIC
      • 5.7.3.1 Japan
      • 5.7.3.2 India
      • 5.7.3.3 China
    • 5.7.4 MIDDLE EAST
      • 5.7.4.1 Saudi Arabia
      • 5.7.4.2 UAE
  • 5.8 TECHNOLOGY ANALYSIS
    • 5.8.1 KEY TECHNOLOGIES
      • 5.8.1.1 Immunoassay techniques
    • 5.8.2 COMPLEMENTARY TECHNOLOGIES
      • 5.8.2.1 Polymerase chain reaction
    • 5.8.3 ADJACENT TECHNOLOGIES
      • 5.8.3.1 Mass spectrometry
      • 5.8.3.2 Flow cytometry
    • TABLE 7 KEY PLAYERS OFFERING ESOTERIC TESTS WITH ADVANCED TECHNOLOGIES
  • 5.9 PATENT ANALYSIS
    • FIGURE 27 PATENT ANALYSIS FOR ESOTERIC TESTING MARKET (JANUARY 2013-DECEMBER 2023)
  • 5.10 KEY CONFERENCES & EVENTS IN 2024-2025
    • TABLE 8 ESOTERIC TESTING MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, 2O24-2025
  • 5.11 PORTER'S FIVE FORCES ANALYSIS
    • FIGURE 28 ESOTERIC TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS
    • TABLE 9 ESOTERIC TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.11.1 INTENSITY OF COMPETITIVE RIVALRY
    • 5.11.2 BARGAINING POWER OF SUPPLIERS
    • 5.11.3 BARGAINING POWER OF BUYERS
    • 5.11.4 THREAT OF SUBSTITUTES
    • 5.11.5 THREAT OF NEW ENTRANTS
  • 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
    • TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS (%)
    • 5.12.2 BUYING CRITERIA
    • FIGURE 30 KEY BUYING CRITERIA FOR ESOTERIC TESTING END USERS
    • TABLE 11 KEY BUYING CRITERIA FOR ESOTERIC TESTING END USERS
  • 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
    • 5.13.1 REVENUE SHIFT IN ESOTERIC TESTING MARKET
  • 5.14 INVESTMENT AND FUNDING SCENARIO

6 ESOTERIC TESTING MARKET, BY TECHNOLOGY

  • 6.1 INTRODUCTION
    • TABLE 12 ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • 6.2 CHEMILUMINESCENCE IMMUNOASSAY
    • 6.2.1 HIGH THROUGHPUT AND REDUCED HUMAN ERROR TO DRIVE MARKET
    • TABLE 13 ESOTERIC TESTING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 14 NORTH AMERICA: ESOTERIC TESTING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 15 EUROPE: ESOTERIC TESTING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 16 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 17 LATIN AMERICA: ESOTERIC TESTING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.3 ENZYME-LINKED IMMUNOSORBENT ASSAY
    • 6.3.1 GROWING NUMBER OF DRUG DISCOVERY ACTIVITIES TO PROPEL MARKET
    • TABLE 18 EXAMPLES OF ESOTERIC ELISA TESTS
    • TABLE 19 ESOTERIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 20 NORTH AMERICA: ESOTERIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 21 EUROPE: ESOTERIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 22 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 23 LATIN AMERICA: ESOTERIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.4 REAL-TIME PCR
    • 6.4.1 INCREASING USE OF QPCR FOR VARIOUS DIAGNOSTIC AND RESEARCH PURPOSES TO SUPPORT MARKET GROWTH
    • TABLE 24 ESOTERIC TESTING MARKET FOR REAL-TIME PCR, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 25 NORTH AMERICA: ESOTERIC TESTING MARKET FOR REAL-TIME PCR, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 26 EUROPE: ESOTERIC TESTING MARKET FOR REAL-TIME PCR, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 27 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR REAL-TIME PCR, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 28 LATIN AMERICA: ESOTERIC TESTING MARKET FOR REAL-TIME PCR, BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.5 DNA SEQUENCING AND NEXT-GENERATION SEQUENCING
    • 6.5.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO AID MARKET GROWTH
    • TABLE 29 EXAMPLES OF ESOTERIC TESTS FOR DNA SEQUENCING
    • TABLE 30 ESOTERIC TESTING MARKET FOR DNA SEQUENCING AND NEXT-GENERATION SEQUENCING, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 31 NORTH AMERICA: ESOTERIC TESTING MARKET FOR DNA SEQUENCING AND NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 32 EUROPE: ESOTERIC TESTING MARKET FOR DNA SEQUENCING AND NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 33 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR DNA SEQUENCING AND NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 34 LATIN AMERICA: ESOTERIC TESTING MARKET FOR DNA SEQUENCING AND NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.6 FLOW CYTOMETRY
    • 6.6.1 RISING PREVALENCE OF CANCER, HIV, AND HEMATOLOGIC MALIGNANCIES TO DRIVE MARKET
    • TABLE 35 ESOTERIC TESTING MARKET FOR FLOW CYTOMETRY, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 36 NORTH AMERICA: ESOTERIC TESTING MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 37 EUROPE: ESOTERIC TESTING MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 38 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 39 LATIN AMERICA: ESOTERIC TESTING MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.7 CHROMATOGRAPHY AND MASS SPECTROMETRY
    • 6.7.1 METHODOLOGICAL IMPROVEMENTS AND TECHNOLOGICAL INNOVATIONS TO BOOST MARKET GROWTH
    • TABLE 40 ESOTERIC TESTING MARKET FOR CHROMATOGRAPHY AND MASS SPECTROMETRY, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 41 NORTH AMERICA: ESOTERIC TESTING MARKET FOR CHROMATOGRAPHY AND MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 42 EUROPE: ESOTERIC TESTING MARKET FOR CHROMATOGRAPHY AND MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 43 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR CHROMATOGRAPHY AND MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 44 LATIN AMERICA: ESOTERIC TESTING MARKET FOR CHROMATOGRAPHY AND MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.8 OTHER TECHNOLOGIES
    • TABLE 45 ESOTERIC TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 46 NORTH AMERICA: ESOTERIC TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 47 EUROPE: ESOTERIC TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 48 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 49 LATIN AMERICA: ESOTERIC TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)

7 ESOTERIC TESTING MARKET, BY TYPE

  • 7.1 INTRODUCTION
    • TABLE 50 ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • 7.2 ONCOLOGY TESTING
    • 7.2.1 HIGH BURDEN OF CANCER TO DRIVE MARKET
    • TABLE 51 PREVALENCE OF CANCER AMONG MALES, 2022
    • TABLE 52 PREVALENCE OF CANCER AMONG FEMALES, 2022
    • TABLE 53 EXAMPLES OF ESOTERIC TESTS FOR CANCER DIAGNOSIS
    • TABLE 54 ESOTERIC ONCOLOGY TESTING MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 55 NORTH AMERICA: ESOTERIC ONCOLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 56 EUROPE: ESOTERIC ONCOLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 57 ASIA PACIFIC: ESOTERIC ONCOLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 58 LATIN AMERICA: ESOTERIC ONCOLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.3 AUTOIMMUNE DISEASE TESTING
    • 7.3.1 RISING PREVALENCE OF AUTOIMMUNE DISEASES TO SUPPORT MARKET GROWTH
    • TABLE 59 ESOTERIC AUTOIMMUNE DISEASE TESTING MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 60 NORTH AMERICA: ESOTERIC AUTOIMMUNE DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 61 EUROPE: ESOTERIC AUTOIMMUNE DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 62 ASIA PACIFIC: ESOTERIC AUTOIMMUNE DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 63 LATIN AMERICA: ESOTERIC AUTOIMMUNE DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.4 INFECTIOUS DISEASE TESTING
    • 7.4.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO AID MARKET GROWTH
    • TABLE 64 EXAMPLES OF ESOTERIC TESTS FOR INFECTIOUS DISEASES
    • TABLE 65 ESOTERIC INFECTIOUS DISEASE TESTING MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 66 NORTH AMERICA: ESOTERIC INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 67 EUROPE: ESOTERIC INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 68 ASIA PACIFIC: ESOTERIC INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 69 LATIN AMERICA: ESOTERIC INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.5 ENDOCRINOLOGY TESTING
    • 7.5.1 INCREASING INCIDENCE OF DIABETES TO DRIVE ADOPTION OF ESOTERIC TESTS
    • TABLE 70 ESOTERIC ENDOCRINOLOGY TESTING MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 71 NORTH AMERICA: ESOTERIC ENDOCRINOLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 72 EUROPE: ESOTERIC ENDOCRINOLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 73 ASIA PACIFIC: ESOTERIC ENDOCRINOLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 74 LATIN AMERICA: ESOTERIC ENDOCRINOLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.6 GENETIC TESTING
    • 7.6.1 ADVANCEMENTS IN GENOMICS AND PROTEOMICS TO SUPPORT MARKET GROWTH
    • TABLE 75 ESOTERIC GENETIC TESTING MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 76 NORTH AMERICA: ESOTERIC GENETIC TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 77 EUROPE: ESOTERIC GENETIC TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 78 ASIA PACIFIC: ESOTERIC GENETIC TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 79 LATIN AMERICA: ESOTERIC GENETIC TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.7 NEUROLOGY TESTING
    • 7.7.1 INCREASING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE MARKET
    • TABLE 80 EXAMPLES OF ESOTERIC TESTS FOR NEUROLOGICAL DISORDERS
    • TABLE 81 ESOTERIC NEUROLOGY TESTING MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 82 NORTH AMERICA: ESOTERIC NEUROLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 83 EUROPE: ESOTERIC NEUROLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 84 ASIA PACIFIC: ESOTERIC NEUROLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 85 LATIN AMERICA: ESOTERIC NEUROLOGY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.8 TOXICOLOGY AND DRUG MONITORING TESTING
    • 7.8.1 INCREASING CASES OF DRUG ABUSE AND ILLICIT DRUG CONSUMPTION TO DRIVE DEMAND FOR ESOTERIC TESTING
    • TABLE 86 ESOTERIC TOXICOLOGY AND DRUG MONITORING TESTING MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 87 NORTH AMERICA: ESOTERIC TOXICOLOGY AND DRUG MONITORING TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 88 EUROPE: ESOTERIC TOXICOLOGY AND DRUG MONITORING TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 89 ASIA PACIFIC: ESOTERIC TOXICOLOGY AND DRUG MONITORING TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 90 LATIN AMERICA: ESOTERIC TOXICOLOGY AND DRUG MONITORING TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.9 OTHER TYPES OF TESTING
    • TABLE 91 ESOTERIC TESTING MARKET FOR OTHER TYPES OF TESTING, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 92 NORTH AMERICA: ESOTERIC TESTING MARKET FOR OTHER TYPES OF TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 93 EUROPE: ESOTERIC TESTING MARKET FOR OTHER TYPES OF TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 94 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR OTHER TYPES OF TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 95 LATIN AMERICA: ESOTERIC TESTING MARKET FOR OTHER TYPES OF TESTING, BY COUNTRY, 2022-2029 (USD MILLION)

8 ESOTERIC TESTING MARKET, BY SPECIMEN

  • 8.1 INTRODUCTION
    • TABLE 96 ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
  • 8.2 BLOOD, SERUM, AND PLASMA
    • 8.2.1 GREATER PREFERENCE AMONG HEALTHCARE PROVIDERS TO PROPEL MARKET
    • TABLE 97 ESOTERIC TESTING MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 98 NORTH AMERICA: ESOTERIC TESTING MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 99 EUROPE: ESOTERIC TESTING MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 100 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 101 LATIN AMERICA: ESOTERIC TESTING MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.3 URINE
    • 8.3.1 INCREASING UTILIZATION IN ILLICIT DRUG TESTING TO BOOST DEMAND
    • TABLE 102 ESOTERIC TESTING MARKET FOR URINE SPECIMENS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 103 NORTH AMERICA: ESOTERIC TESTING MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 104 EUROPE: ESOTERIC TESTING MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 105 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 106 LATIN AMERICA: ESOTERIC TESTING MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.4 OTHER SPECIMENS
    • TABLE 107 ESOTERIC TESTING MARKET FOR OTHER SPECIMENS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 108 NORTH AMERICA: ESOTERIC TESTING MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 109 EUROPE: ESOTERIC TESTING MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 110 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 111 LATIN AMERICA: ESOTERIC TESTING MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)

9 ESOTERIC TESTING MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 112 ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 9.2 INDEPENDENT AND REFERENCE LABORATORIES
    • 9.2.1 LARGEST AND FASTEST-GROWING END USERS OF ESOTERIC TESTS
    • TABLE 113 ESOTERIC TESTING MARKET FOR INDEPENDENT AND REFERENCE LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 114 NORTH AMERICA: ESOTERIC TESTING MARKET FOR INDEPENDENT AND REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 115 EUROPE: ESOTERIC TESTING MARKET FOR INDEPENDENT AND REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 116 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR INDEPENDENT AND REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 117 LATIN AMERICA: ESOTERIC TESTING MARKET FOR INDEPENDENT AND REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • 9.3 HOSPITAL-BASED LABORATORIES
    • 9.3.1 INCREASING NUMBER OF SPECIALTY DIAGNOSTIC TESTS PERFORMED TO SUPPORT MARKET GROWTH
    • TABLE 118 ESOTERIC TESTING MARKET FOR HOSPITAL-BASED LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 119 NORTH AMERICA: ESOTERIC TESTING MARKET FOR HOSPITAL-BASED LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 120 EUROPE: ESOTERIC TESTING MARKET FOR HOSPITAL-BASED LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 121 ASIA PACIFIC: ESOTERIC TESTING MARKET FOR HOSPITAL-BASED LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 122 LATIN AMERICA: ESOTERIC TESTING MARKET FOR HOSPITAL-BASED LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)

10 ESOTERIC TESTING MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 123 ESOTERIC TESTING MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 31 NORTH AMERICA: ESOTERIC TESTING MARKET SNAPSHOT
    • TABLE 124 NORTH AMERICA: ESOTERIC TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 125 NORTH AMERICA: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 126 NORTH AMERICA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 127 NORTH AMERICA: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 128 NORTH AMERICA: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.2.1 NORTH AMERICA: RECESSION IMPACT
    • 10.2.2 US
      • 10.2.2.1 Favorable policies for molecular diagnostic providers to support market growth
    • TABLE 129 US: INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
    • TABLE 130 US: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 131 US: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 132 US: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 133 US: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.2.3 CANADA
      • 10.2.3.1 Lack of proper reimbursements for diagnostic tests to hamper market growth
    • TABLE 134 CANADA: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 135 CANADA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 136 CANADA: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 137 CANADA: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 138 EUROPE: ESOTERIC TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 139 EUROPE: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 140 EUROPE: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 141 EUROPE: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 142 EUROPE: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.3.1 EUROPE: RECESSION IMPACT
    • 10.3.2 GERMANY
      • 10.3.2.1 Favorable government policies to propel market
    • TABLE 143 GERMANY: INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
    • TABLE 144 GERMANY: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 145 GERMANY: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 146 GERMANY: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 147 GERMANY: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Rising demand for early disease diagnosis to drive market
    • TABLE 148 FRANCE: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 149 FRANCE: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 150 FRANCE: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 151 FRANCE: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.3.4 ITALY
      • 10.3.4.1 Rapidly growing geriatric population to favor market growth
    • TABLE 152 ITALY: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 153 ITALY: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 154 ITALY: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 155 ITALY: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.3.5 UK
      • 10.3.5.1 Favorable investment scenario to drive market
    • TABLE 156 UK: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 157 UK: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 158 UK: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 159 UK: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.3.6 SPAIN
      • 10.3.6.1 High burden of chronic and infectious diseases to drive adoption of esoteric tests
    • TABLE 160 SPAIN: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 161 SPAIN: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 162 SPAIN: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 163 SPAIN: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 164 REST OF EUROPE: CANCER INCIDENCE, BY COUNTRY, 2022 VS. 2045
    • TABLE 165 REST OF EUROPE: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 166 REST OF EUROPE: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 167 REST OF EUROPE: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 168 REST OF EUROPE: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 32 ASIA PACIFIC: ESOTERIC TESTING MARKET SNAPSHOT
    • TABLE 169 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 170 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 171 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 172 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 173 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.4.1 ASIA PACIFIC: RECESSION IMPACT
    • 10.4.2 JAPAN
      • 10.4.2.1 Presence of well-developed healthcare system to favor market growth
    • TABLE 174 JAPAN: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
    • TABLE 175 JAPAN: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 176 JAPAN: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 177 JAPAN: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 178 JAPAN: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.4.3 CHINA
      • 10.4.3.1 China to register highest growth rate in Asia Pacific esoteric testing market during forecast period
    • TABLE 179 CHINA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
    • TABLE 180 CHINA: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 181 CHINA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 182 CHINA: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 183 CHINA: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.4.4 INDIA
      • 10.4.4.1 Improving healthcare system to support market growth
    • TABLE 184 INDIA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
    • TABLE 185 INDIA: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 186 INDIA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 187 INDIA: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 188 INDIA: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.4.5 AUSTRALIA
      • 10.4.5.1 Increasing incidence of chronic diseases and increasing focus on preventive healthcare to propel market
    • TABLE 189 AUSTRALIA: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 190 AUSTRALIA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 191 AUSTRALIA: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 192 AUSTRALIA: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.4.6 REST OF ASIA PACIFIC
    • TABLE 193 REST OF ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 194 REST OF ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 195 REST OF ASIA PACIFIC: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 196 REST OF ASIA PACIFIC: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 10.5 LATIN AMERICA
    • TABLE 197 LATIN AMERICA: ESOTERIC TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 198 LATIN AMERICA: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 199 LATIN AMERICA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 200 LATIN AMERICA: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 201 LATIN AMERICA: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.5.1 LATIN AMERICA: RECESSION IMPACT
    • 10.5.2 BRAZIL
      • 10.5.2.1 Presence of large and well-developed pharmaceutical industry to drive market
    • TABLE 202 BRAZIL: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 203 BRAZIL: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 204 BRAZIL: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 205 BRAZIL: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.5.3 MEXICO
      • 10.5.3.1 Growth in private healthcare sector to propel market
    • TABLE 206 MEXICO: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 207 MEXICO: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 208 MEXICO: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 209 MEXICO: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.5.4 REST OF LATIN AMERICA
    • TABLE 210 REST OF LATIN AMERICA: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 211 REST OF LATIN AMERICA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 212 REST OF LATIN AMERICA: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 213 REST OF LATIN AMERICA: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET
    • TABLE 214 AFRICA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
    • TABLE 215 MIDDLE EAST & AFRICA: ESOTERIC TESTING MARKET, BY TEST, 2022-2029 (USD MILLION)
    • TABLE 216 MIDDLE EAST & AFRICA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 217 MIDDLE EAST & AFRICA: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 218 MIDDLE EAST & AFRICA: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 10.7 MIDDLE EAST & AFRICA: RECESSION IMPACT
  • 10.8 GCC COUNTRIES
    • 10.8.1 HEALTHCARE INFRASTRUCTURE DEVELOPMENT TO DRIVE MARKET
    • TABLE 219 GCC COUNTRIES: ESOTERIC TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 220 GCC COUNTRIES: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 221 GCC COUNTRIES: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 222 GCC COUNTRIES: ESOTERIC TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.8.2 GCC COUNTRIES: RECESSION IMPACT

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • TABLE 223 OVERVIEW OF STRATEGIES ADOPTED BY KEY MARKET PLAYERS
  • 11.3 REVENUE SHARE ANALYSIS
    • FIGURE 33 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN ESOTERIC TESTING MARKET, 2021-2023 (USD MILLION)
  • 11.4 MARKET SHARE ANALYSIS
    • TABLE 224 ESOTERIC TESTING MARKET: DEGREE OF COMPETITION
    • FIGURE 34 ESOTERIC TESTING MARKET SHARE ANALYSIS, 2023
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 35 ESOTERIC TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
    • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • TABLE 225 COMPANY FOOTPRINT
    • TABLE 226 TYPE FOOTPRINT
    • TABLE 227 TECHNOLOGY FOOTPRINT
    • TABLE 228 END-USER FOOTPRINT
    • TABLE 229 REGIONAL FOOTPRINT
  • 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 STARTING BLOCKS
    • 11.6.3 RESPONSIVE COMPANIES
    • 11.6.4 DYNAMIC COMPANIES
    • FIGURE 36 ESOTERIC TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
    • 11.6.5 COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
    • TABLE 230 ESOTERIC TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • 11.7 COMPETITIVE SCENARIO
    • 11.7.1 SERVICE LAUNCHES
    • TABLE 231 ESOTERIC TESTING MARKET: SERVICE LAUNCHES, JANUARY 2021-APRIL 2024
    • 11.7.2 DEALS
    • TABLE 232 ESOTERIC TESTING MARKET: DEALS, JANUARY 2021-APRIL 2024
    • 11.7.3 EXPANSIONS
    • TABLE 233 ESOTERIC TESTING MARKET: EXPANSIONS, JANUARY 2021-APRIL 2024
  • 11.8 VALUATION AND FINANCIAL METRICS OF ESOTERIC TESTING VENDORS
    • FIGURE 37 EV/EBITDA OF TOP 3 COMPANIES IN ESOTERIC TESTING MARKET
    • FIGURE 38 EV/REVENUE OF TOP 3 COMPANIES IN ESOTERIC TESTING MARKET
    • FIGURE 39 1-YEAR PRICE TOTAL RETURN OF TOP 3 COMPANIES IN ESOTERIC TESTING MARKET
    • FIGURE 40 5-YEAR BETA OF TOP 3 COMPANIES IN ESOTERIC TESTING MARKET

12 COMPANY PROFILES

  • (Business overview, Products offered, Recent Developments, MNM view)**
  • 12.1 MAJOR PLAYERS
    • 12.1.1 LABCORP
    • TABLE 234 LABCORP: BUSINESS OVERVIEW
    • FIGURE 41 LABCORP: COMPANY SNAPSHOT (2023)
    • TABLE 235 LABCORP: SERVICES OFFERED
    • TABLE 236 LABCORP: SERVICE LAUNCHES, JANUARY 2021-APRIL 2024
    • TABLE 237 LABCORP: DEALS, JANUARY 2021-APRIL 2024
    • TABLE 238 LABCORP: EXPANSIONS, JANUARY 2021-APRIL 2024
    • 12.1.2 QUEST DIAGNOSTICS
    • TABLE 239 QUEST DIAGNOSTICS: BUSINESS OVERVIEW
    • FIGURE 42 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2023)
    • TABLE 240 QUEST DIAGNOSTICS: SERVICES OFFERED
    • TABLE 241 QUEST DIAGNOSTICS: SERVICE LAUNCHES, JANUARY 2021-APRIL 2024
    • TABLE 242 QUEST DIAGNOSTICS: DEALS, JANUARY 2021-APRIL 2024
    • TABLE 243 QUEST DIAGNOSTICS: EXPANSIONS, JANUARY 2021-APRIL 2024
    • 12.1.3 OPKO HEALTH, INC.
    • TABLE 244 OPKO HEALTH, INC.: BUSINESS OVERVIEW
    • FIGURE 43 OPKO HEALTH, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 245 OPKO HEALTH, INC.: SERVICES OFFERED
    • TABLE 246 OPKO HEALTH, INC.: DEALS, JANUARY 2021-APRIL 2024
    • 12.1.4 H.U. GROUP HOLDINGS, INC.
    • TABLE 247 H.U. GROUP HOLDINGS, INC.: BUSINESS OVERVIEW
    • FIGURE 44 H.U. GROUP HOLDINGS, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 248 H.U. GROUP HOLDINGS, INC.: SERVICES OFFERED
    • TABLE 249 H.U. GROUP HOLDINGS, INC.: DEALS, JANUARY 2021-APRIL 2024
    • 12.1.5 SONIC HEALTHCARE LIMITED
    • TABLE 250 SONIC HEALTHCARE LIMITED: BUSINESS OVERVIEW
    • FIGURE 45 SONIC HEALTHCARE LIMITED: COMPANY SNAPSHOT (2023)
    • TABLE 251 SONIC HEALTHCARE LIMITED: SERVICES OFFERED
    • TABLE 252 SONIC HEALTHCARE LIMITED: DEALS
    • 12.1.6 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (MFMER)
    • TABLE 253 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH: BUSINESS OVERVIEW
    • TABLE 254 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH: SERVICES OFFERED
    • 12.1.7 EUROFINS SCIENTIFIC
    • TABLE 255 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 46 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2023)
    • TABLE 256 EUROFINS SCIENTIFIC: SERVICES OFFERED
    • TABLE 257 EUROFINS SCIENTIFIC: SERVICE LAUNCHES, JANUARY 2021-APRIL 2024
    • TABLE 258 EUROFINS SCIENTIFIC: DEALS, JANUARY 2021-APRIL 2024
    • 12.1.8 STANFORD HEALTH CARE
    • TABLE 259 STANFORD HEALTH CARE: BUSINESS OVERVIEW
    • TABLE 260 STANFORD HEALTH CARE: SERVICES OFFERED
    • TABLE 261 STANFORD HEALTH CARE: SERVICE LAUNCHES, JANUARY 2021-APRIL 2024
    • TABLE 262 STANFORD HEALTH CARE: DEALS, JANUARY 2021-APRIL 2024
    • 12.1.9 FOUNDATION MEDICINE, INC.
    • TABLE 263 FOUNDATION MEDICINE, INC.: BUSINESS OVERVIEW
    • TABLE 264 FOUNDATION MEDICINE, INC.: SERVICES OFFERED
    • TABLE 265 FOUNDATION MEDICINE, INC.: DEALS, JANUARY 2021-APRIL 2024
    • 12.1.10 KINDSTAR GLOBALGENE TECHNOLOGY, INC.
    • TABLE 266 KINDSTAR GLOBALGENE TECHNOLOGY, INC.: BUSINESS OVERVIEW
    • FIGURE 47 KINDSTAR GLOBALGENE TECHNOLOGY, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 267 KINDSTAR GLOBALGENE TECHNOLOGY, INC.: SERVICES OFFERED
    • 12.1.11 GEORGIA ESOTERIC & MOLECULAR LABORATORY, LLC
    • TABLE 268 GEORGIA ESOTERIC & MOLECULAR LABORATORY, LLC: BUSINESS OVERVIEW
    • TABLE 269 GEORGIA ESOTERIC & MOLECULAR LABORATORY, LLC: SERVICES OFFERED
    • 12.1.12 THYROCARE TECHNOLOGIES LIMITED
    • TABLE 270 THYROCARE TECHNOLOGIES LIMITED: BUSINESS OVERVIEW
    • FIGURE 48 THYROCARE TECHNOLOGIES LIMITED: COMPANY SNAPSHOT (2023)
    • TABLE 271 THYROCARE TECHNOLOGIES LIMITED: SERVICES OFFERED
    • 12.1.13 ACM GLOBAL LABORATORIES
    • TABLE 272 ACM GLOBAL LABORATORIES: BUSINESS OVERVIEW
    • TABLE 273 ACM GLOBAL LABORATORIES: SERVICES OFFERED
  • 12.2 OTHER PLAYERS
    • 12.2.1 NMS LABS
    • 12.2.2 HEALTHQUEST ESOTERICS
    • 12.2.3 CERBA XPERT
    • 12.2.4 LEOLABS, INC.
    • 12.2.5 FLOW HEALTH
    • 12.2.6 INVITAE CORPORATION
    • 12.2.7 MYRIAD GENETICS, INC.
    • 12.2.8 ARUP LABORATORIES
    • 12.2.9 FULGENT GENETICS
    • 12.2.10 BIOMONTR LABS
    • 12.2.11 LABGENOMICS
  • *Details on Business overview, Products/Services/Solutions offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS